作者
Stanley J Szefler, Richard J Martin, Tonya Sharp King, Homer A Boushey, Reuben M Cherniack, Vernon M Chinchilli, Timothy J Craig, Myrna Dolovich, Jeffrey M Drazen, Joanne K Fagan, John V Fahy, James E Fish, Jean G Ford, Elliot Israel, James Kiley, Monica Kraft, Stephen C Lazarus, Robert F Lemanske Jr, Elizabeth Mauger, Stephen P Peters, Christine A Sorkness
发表日期
2002/3/1
期刊
Journal of Allergy and Clinical Immunology
卷号
109
期号
3
页码范围
410-418
出版商
Mosby
简介
Background
A clinical model is needed to compare inhaled corticosteroids (ICSs) with respect to efficacy.
Objective
The purpose of this investigation was to compare the relative beneficial and systemic effects in a dose-response relationship for 2 ICSs.
Methods
A 24-week, parallel, open-label, multicenter trial examined the benefit-risk ratio of 2 ICSs in persistent asthma. Benefit was assessed by improvements in FEV1 and PC20; risk was assessed by overnight plasma cortisol suppression. Thirty subjects were randomized to either beclomethasone dipropionate (BDP) 168, 672, and 1344 μg/day (n = 15) or fluticasone propionate (FP) 88, 352, and 704 μg/day (n = 15), both administered by means of a metered dose inhaler (MDI) with chlorofluorocarbon propellant via a spacer, in 3 consecutive 6-week intervals; this was followed by 3 weeks of FP dry powder inhaler (DPI) 2000 μg/day.
Results
Maximum FEV1 …
引用总数
学术搜索中的文章
SJ Szefler, RJ Martin, TS King, HA Boushey… - Journal of Allergy and Clinical Immunology, 2002